Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Exact Sciences (EXAS) but lowers the price target from $90 to $85.

May 09, 2024 | 6:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Exact Sciences, but lowers the price target from $90 to $85.
The adjustment in price target by Canaccord Genuity, while maintaining a Buy rating, suggests a positive outlook on Exact Sciences but with a slightly reduced growth expectation. This could lead to a neutral short-term impact on the stock as the market digests the new price target alongside the reaffirmed confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100